A Single Dose Escalation Trial of HRS-2129 in Healthy Subjects

NCT06619392 ↗

Phase 1 Completed 44 enrolled Shandong Suncadia Medicine Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics in healthy subjects, and to evaluate the food effect on pharmacokinetics of HRS-2129.

Timeline

Start: 2024-10-17
Primary completion: 2025-01-20
Completion: 2025-01-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-2129	Unknown	—	—

Indications

No indication recorded.